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Abstract
Background: An important limiting factor in the development of centrally acting pharmaceuticals is the blood-
brain barrier (BBB). Transport of therapeutic peptides through this highly protective physiological barrier remains a
challenge for peptide drug delivery into the central nervous system (CNS). Because the most common strategy to
treat moderate to severe pain consists of the activation of opioid receptors in the brain, the development of active
opioid peptide analogues as potential analgesics requires compounds with a high resistance to enzymatic
degradation and an ability to cross the BBB.
Results: Herein we report that tetrapeptide analogues of the type H-Dmt
1-Xxx
2-Yyy
3-Gly
4-NH2 are transported into
the brain after intravenous and subcutaneous administration and are able to activate the μ- and δ opioid receptors
more efficiently and over longer periods of time than morphine. Using the hot water tail flick test as the animal
model for antinociception, a comparison in potency is presented between a side chain conformationally
constrained analogue containing the benzazepine ring (BVD03, Yyy
3: Aba), and a “ring opened” analogue (BVD02,
Yyy
3: Phe). The results show that in addition to the increased lipophilicity through amide bond N-methylation, the
conformational constraint introduced at the level of the Phe
3 side chain causes a prolonged antinociception.
Further replacement of NMe-D-Ala
2 by D-Arg
2 in the tetrapeptide sequence led to an improved potency as
demonstrated by a higher and maintained antinociception for AN81 (Xxx
2: D-Arg) vs. BVD03 (Xxx
2: NMe-D-Ala). A
daily injection of the studied opioid ligands over a time period of 5 days did however result in a substantial
decrease in antinociception on the fifth day of the experiment. The compact opioid agonist - NK1 antagonist
hybrid SBCHM01 could not circumvent opioid induced tolerance.
Conclusions: We demonstrated that the introduction of a conformational constraint has an important impact on
opioid receptor activation and subsequent antinociception in vivo. Further amino acid substitution allowed to
identify AN81 as an opioid ligand able to access the CNS and induce antinociception at very low doses (0.1 mg/
kg) over a time period up to 7 hours. However, tolerance became apparent after repetitive i.v. administration of the
investigated tetrapeptides. This side effect was also observed with the dual opioid agonist-NK1 receptor antagonist
SBCHM01.
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Opioids are the most widely used analgesics in the treat-
ment of various pain states. Early binding studies and
functional bioassays defined three main types of opioid
receptors in the central nervous system: μ-( M O R ) ,δ-
(DOR) and - (KOR) receptors [1,2]. The μ-opioid recep-
tor was identified to be essential for an efficient antinoci-
ception in acute and severe pain models. Aside from the
desired pain-relieving action, prolonged exposure to μ
opioids results in well established, undesired side effects,
including sedation, respiratory depression, physical depen-
dence and analgesic tolerance [3,4]. Several studies how-
ever provided evidence that compounds with a dual
MOR/DOR activity present beneficial pharmacological
effects in comparison to highly selective MOR agonists
[5]. It was, for example, demonstrated that the analgesic
efficacy of MOR agonists can be enhanced by DOR ago-
nists [6,7]. Moreover, mixed MOR agonism/DOR (ant)
agonism can suppress or eliminate the development of
physical dependence, tolerance and respiratory depression,
adverse effects which are typically observed for selective
MOR agonists [5,8,9]. Because of these promising indica-
tions, compounds which combine MOR agonism with
DOR (ant)agonism have received a great deal of attention
as lead structures towards novel opioid analgesics.
A limitation of most peptides for use as analgesics
consists of their limited access to the brain. This draw-
back is not only due to their poor metabolic stability,
but also a consequence of their low lipid solubility and
limited ability to cross the blood-brain barrier (BBB)
[10]. Several strategies have been developed to overcome
the hurdle of opioid peptide drug delivery to the brain,
including structural modifications such as glycosylation
[10,11], lipid conjugation [12], and various types of
cyclization [13-15]. In this way researchers attempt to
modulate the balance of hydrophobic-hydrophilic prop-
erties of the compounds and to decrease the number of
accessible conformations, which can potentially result in
an increased membrane permeability. Despite the pre-
paration and evaluation of a plethora of bioactive opioid
ligands, both peptidic and non-peptidic, an alternative
to morphine, the golden standard in moderate to severe
pain research, has yet to be found.
An alternative to the preparation of compounds which
solely target the opioid system consists of the creation
of hybrid compounds that interact with multiple biologi-
cally relevant targets [16-18]. The emerging strategy to
design and synthesize chimeras, also called designed
multiple ligands (DMLs), as a promising alternative to a
treatment by monotherapy, is justified by the fact that
such compounds are commonly characterized by not
only a high activity, but more importantly present the
possibility to improve the pharmacological profile by
selectively ‘designing out’ an undesired biological char-
acteristic, both in terms of action or transport [19,20].
As such, the chemical structure of the drug allows to
modulate the permeability of the active substance and in
consequence create “site specificity of action” [9,16]. The
precision of action of these kinds of compounds can be
built up by the knowledge about their specific activity as
single molecules. By hybridizing two active compounds
into one chemical entity it is possible to develop drugs
which may provide a superior delivery capacity, as com-
pared to the delivery of a physical mixture of the drugs.
When applied to pain research the combination of an
opioid pharmacophore and a NK1 receptor antagonist
led to a new type of bifunctional drugs which aim at a
prolonged therapeutic efficiency over time [21-24]. Sub-
stance P, an 11-amino acid peptide belonging to the
tachykinin family, is known to be important for trans-
mission of nociceptive signals [25]. The design rationale
of the opioid-NK1 DMLs originates from the upregula-
tion of the pronociceptive neurotransmitter substance P
and its receptor, the neurokinin 1 receptor (NK1R),
upon chronic administration of opioids [26,27]. The
NK1 antagonist pharmacophore in these DMLs could
potentially counter the enhanced expression of sub-
stance P and its preferential receptor, NK1R.
From our previous results, we selected three opioid
tetrapeptides with promising in vitro potency for further
in vivo evaluation. All three reported peptide analogues
were derived from dermorphin (H-Tyr-D-Ala-Phe-Gly-
Tyr-Pro-Ser-NH2) as this exogenous peptide proved to
have a high affinity and selectivity for the MOR [28,29].
Additionally, its use as a lead structure was also moti-
vated by the fact that dermorphin, when administered
centrally or peripherally in rodents, induces less toler-
ance development when compared to morphine [30].
We recently identified the opioid ligands H-Dmt-NMe-
D-Ala-Phe-Sar-NH2 (BVD02) [31], H-Dmt-NMe-D-Ala-
Aba-Gly-NH2 (BVD03 with Aba: 4-amino-1,2,4,5-tetra-
hydro-2-benzazepin-3-one, see Figure 1) [31] and H-
Dmt-D-Arg-Aba-Gly-NH2 (AN81) [32] to be potent
compounds in vitro (Figure 1 and Table 1). The N-
terminal Tyr
1 present in dermorphin was replaced by
2’,6’-dimethyl-(S)-tyrosine (Dmt) to improve the enzy-
matic stability, receptor affinity and opioid potency [33],
whereas a conformationally constrained aminobenzaze-
pinone (Aba) moiety placed in third position maintained
MOR affinity as well as activation and resulted in a
favorable increase in DOR binding and activity [34-36].
The Aba benzazepine moiety was also used as a cen-
tral scaffold in the design of a compact bifunctional
ligand, SBCHM01, which possessed the desired dual
opioid agonist - NK1R antagonist activity in vitro (Fig-
ure 1 and Table 1) [32].
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tide derivatives after peripheral (intravenous i.v. and
subcutaneous s.c.) administration in mice in order to
verify their ability to cross the BBB and produce cen-
trally induced analgesia. In addition, the analgesic
potency of a compact hybrid opioid agonist - NK1R
antagonist ligand (SBCHM01) was determined to inves-
tigate the influence of the NK1 pharmacophore incorpo-
rated at the C-terminus of the opioid subunit. The
propensity of all four peptides to induce tolerance after
repetitive administration in mice is reported.
Results
In vivo antinociception of the opioid tetrapeptides
BVD02, BVD03, AN81 and the hybrid opioid agonist -
NK1R antagonist SBCHM01
The antinociceptive potency of three opioid tetrapep-
tides H-Dmt-NMe-D-Ala-Phe-Sar-NH2 (BVD02), H-
Dmt-NMe-D-Ala-Aba-Gly-NH2 (BVD03) [31] and H-
Dmt-D-Arg-Aba-Gly-NH2 (AN81) [32], and of the
hybrid opioid-NK1 structure H-Dmt-D-Arg-Aba-Gly-
NMe-3’,5’-Bn(CF3)2 (SBCHM01) was investigated after
peripheral administration. Following a previously
reported procedure [37], each compound was adminis-
tered intravenously into mice and the hot water tail-flick
test was used to measure the analgesic effect induced by
these compounds.
The time- (F(4;23) = 24.41) [38,39] and dose-dependent
(F(3;23) = 6.006) curves of analgesic response induced by
the BVD02 opioid tetrapeptide, are presented in Figure
2A. BVD02 injected at a dose of 5 mg/kg produces a
strong analgesic effect, which reaches the maximum
level at the early time point of 15 min post-injection (%
MPE = 100) and remains unchanged within the next
hour. Only at 2 h after its administration a slight
decrease in activity is observed (%MPE = 96 ± 4; p >
Figure 1 Structures of opioid ligands BVD02, BVD03, AN81 and opioid-NK1 chimera SBCHM01.
Table 1 In vitro functional activities and affinities of opioid- and opioid-NK1 ligands
Compound NK1R pA2
a hNK1R
Ki (nM)
b
MOR EC50 (nM)
c, d DOR
EC50 (nM)
c, d
MOR
Ki
(nM)
e, f
DOR
Ki
(nM)
e, f
KOR
Ki
(nM)
e, f
BVD02 / / 0.079 ±
0.0065
c
4400 ± 500
c 60 ± 3
e 130 ± 5
e >1 0
6e
BVD03 / / 0.00174 ± 0.00034
c 0.016 ± 0.009
c 15 ± 2
e 5±3
e >1 0
6e
AN81 // 0.32 ± 0.04
d 0.42 ± 0.02
d 0.15 ± 0.02
f 0.60 ± 0.07
f 118 ± 12
f
SBCHM01 7.8 0.5 ± 0.1 8.51 ± 0.62
d 43.3 ± 6.3
d 0.416 ± 0.012
f 10.4 ± 0.6
f 445 ± 81
f
a The pA2 value was calculated using the Schild’s equation [47].
b Inhibitory constants (Ki) of NK1 receptor ligands, measured for the receptor prototype [
3H]-SP in
the presence of hNK1-CHO membranes. Results are means ± SEM of three independent experiments. Binding data were calculated using the nonlinear
regression/one site competition fitting options of the GraphPad Prism Software.
c Agonist properties of peptides on forskolin-stimulated cAMP accumulation by
MOR and DOR [31,48].
d Values represent means of 3-6 experiments ± SEM in the GPI (functional assay is representative of MOR activation) and MVD (DOR-
representative assay) tissue bioassays [32,49].
e Binding affinities of compounds for MOR and DOR were determined by displacing [
3H]diprenorphine in HEK293
cells stably expressing MOR, DOR and KOR [31].
f Displacement of [
3H]DAMGO and [
3H]DSLET, respectively, from rat brain membrane binding sites and binding
affinities for  opioid receptors were measured by displacement of [
3H]U69,593 from guinea pig brain membrane binding sites [32].
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phine (4 mg/kg) (%MPE = 95.08 ± 1.67). In contrast,
B V D 0 2a td o s e so f1a n d0 . 5m g / k gd i s p l a y sn o t i c e a b l y
lower antinociceptive activity. The highest BVD02-
mediated antinociception is reached at 30 min (1 mg/kg;
%MPE = 74.77 ± 13.63; p > 0.05) and at 60 min (0.5
mg/kg; %MPE = 56.77 ± 13.57; p > 0.05), respectively.
At the next time point (120 min post-injection) a dra-
matic reduction of activity is observed (p < 0.001) when
compared to morphine.
BVD03 was administered into mice at four different
doses, ranging from 0.25 mg/kg to 4 mg/kg, and pro-
duced time- (F(4;32) = 33.15) and dose-dependent (F(4;32)
= 3.166) antinociceptive activity as depicted in Figure
2B. Interestingly, analgesia induced by this compound
injected at a dose of 4 mg/kg seems to be weaker than
that induced by morphine at the same dose (4 mg/kg).
The highest analgesic activity of BVD03 (4 mg/kg) is
observed at 1 h post-injection (%MPE = 68.78 ± 7.18; p
> 0.05). The following measurement at 120 min after
drug injection results in significant reduction of analge-
sia, when compared to morphine (%MPE = 50.06 ±
6.84; p < 0.05). The subsequently investigated doses of
BVD03 (1 mg/kg and 0.5 mg/kg) produced comparable
antinociceptive responses at 60 min and 120 min post-
injection. The calculated percentage of the maximal pos-
sible effect for the concentration of 1 mg/kg is: %MPE =
89.21 ± 5.22 (60 min; p > 0.05) and %MPE = 86.69 ±
5.52 (120 min; p > 0.05), whereas for BVD03 adminis-
tered at 0.5 mg/kg the MPE values are 88.41 ± 7.15 (60
min; p > 0.05) and 84.29 ± 6.46 (120 min; p > 0.05),
respectively.
A decrease in analgesic response of BVD03 injected
into mice is observed at a dose of 0.25 mg/kg. Remark-
a b l y ,c o m p a r i n gt od o s e so f4a n d0 . 5m g / k g ,as i m i l a r
antinociceptive effect (%MPE = 35-40%) induced at 15
min post-injection is seen. However, at further time
points dose-response curves are characterized by having
distinct profiles. In case of BVD03 (0.25 mg/kg) a gra-
dual growing profile, reaching the maximum level of %
MPE = 57.48 ± 17.57 at 2 h post-injection, is recorded.
In all cases, except at a dose of 0.25 mg/kg, the con-
formationally constrained peptide analogue BVD03
shows a drop in antinociception after 2 hours. Given
this observation it was decided that additional assays
over longer time periods were redundant.
The analogous tetrapeptide analogue AN81, H-Dmt-
D-Arg-Aba-Gly-NH2, differs from BVD03 by only one
Figure 2 The dose- and time-dependent analgesic activity of A) BVD02, B) BVD03, C) AN81 and D) SBCHM01 after i.v. injection at two
to four different doses and in comparison with morphine (4 mg/kg, i.p.) Each compound was tested using C57Bl6 male mice and hot
water tail-flick test was used. Data are represented as the % of maximal possible effect (%MPE) ± SEM of 6-10 mice. Statistics conducted using
a two-way analysis of variance (ANOVA) followed by Bonferroni’s test showed significant differences (*p < 0.05; **p < 0.01; ***p < 0.001)
between the examined peptides and morphine. Differences are defined as: * for BVD02 (1 mg/kg) and # for BVD02 (0.5 mg/kg); * for BVD03 (4
mg/kg); # BVD03 (1 mg/kg); $ BVD03 (0.5 mg/kg) and * for AN81 (0.1 mg/kg).
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2 vs. NMe-D-Ala
2,r e s p . ) ,a n d
proved to possess a superagonist profile after in vitro
evaluation [32]. In the functional GPI and MVD tissue
bioassays, the measured subnanomolar EC50 values were
0.32 nM and 0.42 nM and corresponding subnanomolar
binding affinity was observed (Kiμ 0.15 nM and Kiδ 0.60
nM).
In contrast to BVD03, AN81 induces very consistent
high antinociceptive responses even at low doses as
shown in Figure 2C. When administered at a dose of 4
mg/kg, the opioid ligand AN81 exhibits an effect com-
parable to the effect induced by the same compound at
a 4-fold lower dose (1 mg/kg). At the 30 min post-injec-
tion time point the %MPE values for both 4 and 1 mg/
kg doses are %MPE = 100 (p > 0.05) and %MPE = 95 ±
2.89 (p > 0.05), respectively. Interestingly, a two-way
ANOVA followed by Bonferroni’s post-hoc test, shows
no difference in the analgesic effect between first three
drug doses examined doses (4 mg/kg, 1 mg/kg and 0.5
mg/kg) and morphine at all investigated time points (p
> 0.05). In contrast, this compound induced a signifi-
cantly lower analgesic effect, with respect to intraperito-
neally (i.p.) administered morphine (4 mg/kg), at a low
dose of 0.1 mg/kg at 15 min and 120 min after injection.
However, the percentage of maximal possible effect
exceeds 50% reaching the value %MPE = 61.2 ± 6.45 (p
< 0.05) even after 2 h which illustrates the long duration
of action of this compound.
Next, both opioid tetrapeptide ligands BVD03 and
AN81 were also examined with regard to their propen-
sity to induce tolerance development (Figure 3). For this
purpose, each compound was injected intravenously at a
d o s eo f4m g / k ga n da5d a y - l o n gc h r o n i ct r e a t m e n t
was carried out.
The systemic and repeated administration (a daily
regimen for 5 days) of both compounds leads to the
development of tolerance (Figure 3B). On the first day
of drug application both BVD03 and AN81 induce
strong antinociceptive responses. BVD03 is again char-
acterized as being a weaker analgesic than AN81. While
AN81 develops almost constant analgesia, which varies
between 94 and 100% of MPE starting from 15 min
post-injection until the last time point (2 h), the increase
in antinociceptive activity of BVD03 halts 1 h post-injec-
tion, reaching a %MPE = 68.78 ± 7.18 (Figure 3A). On
the fifth day of the experiment the maximum level of
AN81-mediated analgesia is reached 30 min post-injec-
tion where it still shows a %MPE = 34.99 ± 7.32 (p <
0.001), whereas with BVD03 only a low MPE value of %
MPE = 18.14 ± 6.84 was determined after 60 min. At
subsequent time points the pain-relieving action of
AN81 is gradually reduced, achieving at the last time
point the MPE value of 15.83% ± 4.40 (p < 0.001).
In order to further investigate the duration of action
of AN81, the radiant heat tail-flick test was used, which
allowed the measurement of the analgesic response over
a longer time period. The antinociceptive effects of
AN81 were measured up to 7 h after s.c. administration
in mice. (Figure 4).
The antinociceptive activity of AN81 was determined
after s.c. administration of 0.2, 0.5 and 1 mg/kg. As
shown in Figure 4, AN81 produced dose-dependent
effects with a peak of antinociception action at 1 h after
administration at all three doses. After this time point
and within further time points a slow but constant
decrease in activity is observed. It is however remarkable
that an antinociceptive effect is measured up to seven
hours after s.c administration of AN81 at a dose of 1
Figure 3 Analgesic effect induced by chronic intravenous injection of AN81 and BVD03 opioid peptides at a dose of 4 mg/kg.T h e
examined drugs were administered daily for five days (between 10 and 12 am). The determination of nociceptive responses was done on the
first (Figure 3A) and fifth day (Figure 3B) of the experiment. %MPE ± SEM of 7-10 animals per group. On the first day of measurements BVD03,
but not AN81, show significant differences (**p < 0.01) when compared to morphine. Additionally, # represents differences which occur between
examined compounds compared to each other. In contrast, on the fifth day statistics do not show any significant differences (*p < 0.05; **p <
0.01;***p < 0.001).
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trast to morphine for which the activity drops rapidly
over time.
Next, we focused on the pharmacological role that an
additional NK1R pharmacophore could have in these
opioid tetrapeptide ligands. After establishment of the
potent in vitro antinociceptive effect of SBCHM01 [32]
an analgesic animal assay in vivo would provide infor-
mation on: i) whether or not this type of chimeric com-
p o u n di sa c t u a l l ya b l et oc r o s st h eB B B ,i i )a n y
potentiation/synergy of the analgesic effect due to the
NK1R antagonist subunit being present in this chimeric
molecule and iii) if tolerance can be suppressed or even
eliminated by the presented hybrid approach, as sug-
gested in the literature [40,41].
Figure 2D shows a significant analgesic effect after
administration of the hybrid peptide SBCHM01 at two
different doses. As it can be observed that i.v. adminis-
tration of SBCHM01 at a dose of 2 mg/kg produces a
similar antinociceptive response as compared to a dose
of 4 mg/kg. This observation is most prominent in the
later time points, i.e. 1 h and 2 h post-injection. More-
over, at the last time point of the measurement, the %
MPE for both examined doses as well as for morphine
(4 mg/kg) is at the same level and varies between 80.47
± 5.29 (4 mg/kg), 85.12 ± 5.43 (2 mg/kg) and 95.08 ±
1.67 (morphine, 4 mg/kg).
After comparison with the above mentioned opioid-
induced tolerance of BVD03 and AN81 (Figure 3), we
observed similar results after chronic administration of
SBCHM01 (Figure 5 and 6). As can be seen from these
graphs, an injection of this chimera on the first day at a
dose of 4 mg/kg induces a strong time-dependent (F
(4;17) = 13.81) analgesic response (Figure 2D, 5A). How-
ever, when compared with i.p. administered morphine
given at the same dose, SBCHM01 seems to be slightly
weaker during the whole period of measurements. This
also correlates with the reported in vitro data which
indicated that, relative to AN81, SBCHM01 possessed a
reduced in vitro activity in both the GPI and MVD
assay (Table 1). At 2 h post-injection, the %MPE values
of 80.47 ± 5.29 (p > 0.05) and 95.08% ± 1.67 are reached
for SBCHM01 and morphine, respectively.
Subsequently, a daily injection of both morphine and
SBCHM01 was carried out over a 5-day period in order
to verify whether these compounds are prone to the
development of tolerance. Unfortunately, on the fifth
day of the experiment mice had developed opioid-
induced tolerance (Figure 5B), only weak analgesia still
being observed (time-point of 30 min; %MPE = 12.25 ±
7.33).
The repetitive administration of SBCHM01 was also
performed using a 2-fold lower dose (2 mg/kg) and an
additional measurement at 180 min post-injection was
carried out. At that time point a decrease in potency is
clearly visible for both SBCHM01 and morphine (Figure
6A).
As can be seen from Figure 6, lowering the i.v. bolus
dose from 4 to 2 mg/kg does not alter the antinocicep-
tive activity significantly (cfr. Figure 5A) as it still
Figure 4 Dose and time dependent analgesic effects of AN81 after s.c. administration in the radiant heat tail-flick test.A N 8 1o r
morphine was injected s.c. into CD1 mice. Data are %MPE ± SEM of 5-6 mice.
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Again, a gradual build-up of SBCHM01-mediated
analgesia is seen up to 120 min post-injection (%MPE =
85.12 ± 5.43). However, on the first day of the experi-
ment, 3 h after drug administration, a moderate reduc-
tion of analgesia is observed (%MPE = 71.13 ± 4.71).
Additionally, from the acquired data we could conclude
that a lower dose of SBCHM01 does not reduce the
extent of tolerance development (Figure 6B).
Discussion
The potent antinociceptive effects of the investigated
structures after peripheral administration indicate that
all four peptidic compounds are able to cross the BBB.
The antinociceptive enhancement concomitant with the
introduction of a conformational constraint at the level
of the Phe
3 residue (BVD02 vs. BVD03) indicates that
next to molecular lipophilicity, an additional factor for
efficient analgesia in these peptidic ligands consists of
the limitation in conformational flexibility. The observed
effects are in agreement with earlier in vitro binding
data obtained for these peptides (BVD02®BVD03: Kiμ
60 ® 15 nM, Kiδ 130 ® 5n M ,T a b l e1 )[ 3 1 ] ,w h i c h
also confirm that the conformational restriction imposed
by the Aba moiety maintains the MOR binding affinity
of the ligands, but substantially ameliorates DOR bind-
ing. The receptor affinities were in agreement with func-
tional in vitro MOR and DOR activity, as determined by
a functional forskolin-stimulated cAMP accumulation
assay (BVD02®BVD03: EC50μ 0.079 ® 0.00174 nM,
EC50δ 4400 ® 0.016 nM, Table 1) [31]. The aforemen-
tioned role of delta receptors in the modulation of effi-
cacy of MOR agonists needs to be considered at this
point. Next to the MOR activation needed for effica-
cious analgesia, the superior MOR binding and potency
of BVD03 in comparison to BVD02 (factor of 4 and 45,
respectively), is accompanied by a 26-fold increase in
D O Ra f f i n i t ya n da1 0
4 gain in DOR potency. Given the
proposed synergy of mixed MOR agonists-DOR agonists
in analgesia, it is likely that both MOR and DOR com-
ponents of BVD03 are responsible for the enhanced in
vivo antinociception when compared to BVD02. The
activity data suggest that next to the N-methylation in
the “ring opened” BVD02, leading to an increased lipo-
philicity and potentially higher bioavailability, an addi-
tional constraint of the Phe side chain by use of Aba in
BVD03 is also beneficial for antinociception (Figure 2A
and 2B).
In an earlier study, and based on the peptide sequence
of the lead MOR agonist Dmt
1-DALDA (H-Dmt-D-Arg-
Phe-Lys-NH2) [42], which is a potent opioid analgesic
[18], we prepared and evaluated the in vitro pharmaco-
logical opioid profile of H-Dmt-D-Arg-Aba-Gly-NH2
(AN81). This compound was also identified as a full
MOR/DOR agonist with subnanomolar affinity and tis-
sue bioactivity (Table 1) [32]. The structure differs from
BVD03 only in the amide nitrogen N-methyl group and
side chain of the second residue in the peptide sequence
(Figure 1). When an activity comparison is made
between the two peptides at different doses (see Figure
2B and 2C), AN81 seems to produce a faster build-up
in antinociceptive response over time at a dose of 4 mg/
kg, which also seems to be maintained during the first
two hours of measurements. From Figure 3, we con-
cluded that at that dose of 4 mg/kg AN81 is superior to
B V D 0 3a n df u r t h e r m o r ep o s s e s s e sav e r yh i g h% M P E
value even after two hours. AN81’s remarkable antinoci-
ceptive potency is observed at doses ranging from 4 mg/
kg (i.v.) to 0.5 mg/kg (i.v.) (Figure 2C), showing that by
lowering the dose there is the possibility to obtain the
same long-lasting pain-relieving effect. To have a better
idea of the total duration of action of the best tetrapep-
tide analogue (AN81), an additional in vivo pain test
was used. We switched to the radiant tail-flick assay to
avoid the infliction of a possible tail injury after repeti-
tive measurements in the hot-water test. Such an injury
c o u l di nt u r nr e s u l ti nt h eerroneous measurements of
antinociception as observed in earlier studies by our
group upon chronic administration of potent drugs.
A subcutaneous (s.c.) administration of AN81 at three
different doses (1, 0.5 and 0.2 mg/kg) induced marked
analgesia lasting up to 7 hours, whereas morphine lost
almost all activity over a time period of 2 hours at more
elevated doses, relative to AN81 (Figure 4). Because of
the in vivo potency and long duration of action, these
results place AN81 on the list of potentially promising
active lead compounds for acute pain treatment.
The ability of the two most active compounds AN81
and BVD03 to circumvent one of morphine’s major and
highly problematic side effects, the development of tol-
erance upon chronic opioid administration was subse-
quently tested. Figure 3 clearly demonstrates that a daily
dose of both peptide ligands generate an important
reduction in antinociception of the fifth day of the
experiment. Only the most active derivative, AN81,
showed a partially preserved activity with a maximum
(ca. 35%MPE) at the time point of 30 min post-injec-
tion. An observation which can potentially be correlated
to the balanced MOR/DOR agonism of AN81.
The combination of an opioid pharmacophore and a
NK1 receptor antagonist in one chemical entity has
been identified as an approach towards a new type of
bifunctional drugs which aim at a prolonged therapeutic
efficiency over time [21-24]. When a 3’,5’-bistrifluoro-
methyl benzyl moiety is coupled to the C-terminus of
AN81, a compound with dual opioid - NK1 in vitro
activity results (Table 1) [32]. After systemic injection,
SBCHM01 produced a significant dose- and time-
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6, resp.). The inferior antinociceptive effect of this chi-
mera, when compared to its ‘pure’ opioid analogue
AN81 (Figure 2C and 2D), could not only be ascribed to
a diminished MOR affinity and activation (Table 1), but
is also in agreement with the large decrease in DOR
binding and potency (17- and 103-fold, resp.). The
results obtained for SBCHM01 indicate that neither an
synergistic nor potentiating antinociceptive effect
appears when both pharmacophores are combined in a
single chemical entity.
The opioid-induced development of tolerance
observed with BVD03 and AN81 (Figure 3), was in this
study unfortunately not reduced by the additional pre-
sence of a NK1R antagonist pharmacophoric group
covalently attached to the C-terminus of the opioid tet-
rapeptide AN81 (Figures 5 and 6). Concomitant with
the substantial loss of DOR agonism in SBCHM01, the
beneficial property of dual MOR/DOR agonists in
lowering opioid-induced tolerance is unfortunately
eliminated, and could explain the complete loss in anti-
nociception on the fifth day of the experiment. This in
contrast to the partial preservation of analgesia observed
after repetitive administration of AN81, a balanced and
potent MOR/DOR agonist. (Figure 3).
Recently, Vanderah and coworkers [43] reported the
detailed in vivo evaluation of H-Tyr-D-Ala-Gly-Phe-
Met-Pro-Leu-Trp-O-3’,5’-Bn(CF3)2 (TY005) in several
animal assays to define the role of this compound in
thermal and tactile stimuli in uninjured, sham- and
nerve-injured male, Sprague-Dawley rats. They observed
that this compound was able to exert the desired dual
activity in vivo. The opioid agonist activity and NK1R
antagonism were demonstrated in independent assays in
which one of the two activities was isolated by blocking
the second functionality. The authors showed that the
development of antihyperalgesic tolerance could be sup-
pressed by this multimodal ligand. This compound was
Figure 5 SBCHM01-induced tolerance after systemic administration. SBCHM01 was injected i.v. at a dose of 4 mg/kg daily for 5 days. The
results scored as %MPE were compared with morphine (i.p.) at the same dose. (A) The SBCHM01-mediated antinociception measured on the
first day of the study; (B) Reduction of SBCHM01 analgesic activity on the fifth day of the experiment. Each column represents mean ± SEM of
8-10 mice. ***p < 0.001 significantly different from morphine-injected animals.
Figure 6 Comparison of a time-response profile of SBCHM01 (2 mg/kg, i.v.) and morphine (4 mg/kg, i.p.) after chronic administration
into mice and prolonging the experiment time up to 3 h. A) SBCHM01-mediated analgesia on the first day of measurements; B) Complete
abolishment of SBCHM01’s antinociceptive activity on the fifth day of the experiment.
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cing a Dmt residue in position 1 and replacing the
metabolically labile ester function by an amide group
and demonstrated that these changes resulted in
improved opioid agonism, while maintaining NK1 activ-
ity [24].
Upon comparison of this study with related work by
other research teams [43,44], it is however important to
point out that different animal models and conditions
(animals, assay type, drug delivery) were applied. In the
recent publication of Largent-Milnes et al. [43] the inhi-
bition of antihyperalgesic tolerance with the hybrid
opioid-NK1 TY005, was demonstrated after i.t. adminis-
tration and by use of the paw withdrawal test. This is in
contrast to the current study, where the hot water tail-
f l i c ka s s a ys e r v e da sam o d e lf o ra c u t ep a i na n di n
which the drug was injected intravenously. The various
types of noxious stimuli employed in the experimental
paradigms, as well as the different administration routes,
make it difficult to rationalize the different mechanisms
that are responsible of this apparent discrepancy.
Conclusions
In the present study AN81 (H-Dmt-D-Arg-Aba-Gly-
NH2) exhibits the strongest analgesic effect, when admi-
nistered systemically, which suggests that this peptido-
mimetic has the capacity to penetrate the highly
selective blood brain barrier. Moreover, this opioid tet-
rapeptide analogue is characterized by a long duration
of action after subcutaneous injection and proved to be
more active than a very similar structure with a NMe-
D-Ala residue in the second position of the sequence, i.
e. BVD03. This conformationally restricted peptide
l i g a n dp r o v e di nt u r nt ob em o r ep o t e n tt h a ti t s“ring
opened” analogue BVD02.
Unfortunately, AN81 appeared to still induce the
development of tolerance after repetitive administration
over a time period of five days when tested in the hot
water tail-flick test. When compared to morphine, the
induced tolerance was however markedly lower. A simi-
lar result was obtained for the bifunctional opioid ago-
nist-NK1R antagonist ligand, SBCHM01. This peptidic
chimera was, in analogy with the ‘pure’ opioid ligands,
capable of reaching and activating opioid receptors in
the CNS, but it lost its antinociceptive potency comple-
tely upon chronic injection as determined in the hot
water tail-flick assay.
The apparent inability of SBCHM01 to suppress toler-
ance development appears to oppose recent reports by
Vanderah and coworkers [43] which indicate that a
hybrid opioid-NK1 octapeptide ligand (TY005) was able
to attenuate tolerance development related to sustained
opioid pathophysiology in an hyperalgesic model after
central (i.t.) administration, as opposed to this study in
which i.v. administration was used in an acute pain
model. For a general clinical applicability, an important
goal in pain research consists of the discovery and
development of improved analgesic drugs which could
be administered systemically. Hence, we are convinced
that unravelling the cause of this intriguing discrepancy
is important and will consequently be the target of our
future SAR studies.
Methods
In vivo measurement of drug-induced analgesia
A) Intravenous drug administration
Nociceptive responses to thermally-induced pain were
assessed by the hot water tail-flick test [45] using male
C57Bl6 mice. Animals (weighing 25-28 g) were main-
tained on a normal light-dark cycle and testing occurred
during the light cycle. Mice were injected intravenously
(i.v.) with the examined drug, dissolved in saline, at dif-
ferent doses. For the verification of drug-induced anti-
nociceptive tolerance, the investigated compounds were
administered (i.v.) once per day for 5 days (2 and 4 mg/
kg for SBCHM01 and 4 mg/kg for both AN81 and
BVD03) and the analgesic effect was measured on the
first and the fifth day of the experiment. In each case
(both acute and chronic treatment) the effect was mea-
sured over a minimum time period of 120 minutes. The
antinociceptive effect was measured in triplicate at the
following time points post-injection: 5, 15, 30, 60, 120
min (and 180 min for SBCHM01; due to the strong and
long-lasting analgesic effect produced by AN81 (Figure
2C), there was no possibility to prolong the experiment,
which - if prolonged - could in consequence cause
major damage to the animal’s tail, thus giving spurious
nociceptive responses). Responses to thermal hot stimu-
lus were assessed by the latency with which the mouse
removed its tail from 55°C water. A cut-off time of 10 s
was used in order to prevent tissue damage.
The antinociceptive activity exhibited by all analogues
were determined as a percentage of the maximal possi-
ble effect (%MPE) calculated as: %MPE = [(posttreat-
ment latency - baseline latency)/(cut-off latency -
baseline latency)] × 100. In order to compare the anti-
nociceptive effect induced by the examined drugs, mor-
phine was used as a standard reference.
All experimental procedures used in this animal test-
ing followed the guidelines on ethical standards for the
investigation of experimental pain in animals and were
approved by the Animal Research Committees of the
Medical Research Centre, Polish Academy of Sciences.
B) Subcutaneus drug administration
In order to determine the duration of drug activity, s.c.
drug administration into male CD1 mice (27-33 g;
Charles River Laboratories, Sulzfeld, Germany) was per-
formed. In addition to a thermal nociceptive stimulus,
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performed using an UB 37360 Ugo Basile analgesi-
ometer (Ugo Basile s.r.l., Varese, Italy). The reaction
time required by the mouse to remove its tail due to the
radiant heat was measured and defined as the tail-flick
latency. A cut-off time of 10 s was used in order to
minimize tissue damage. Tail-flick latencies were mea-
sured before (baseline) and after drug s.c. administration
(30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h and 7 h), the antino-
ciceptive effect was scored as a percentage of the maxi-
mal possible effect (% MPE), according to formula
presented above. Drugs were dissolved in sterile physio-
logical saline (0.9%) and were administered s.c. in a
volume of 10 μl per 1 g body weight. The animal proce-
dures were approved by the Austrian Ethical Committee
on Animal Care and Use in line with international laws
and policies.
Statistical analysis
Data are presented as means ± standard errors of the
mean (SEM). All of the calculations and statistical analy-
sis were performed using Prism 5.0 (Graph Pad Soft-
ware, San Diego, CA, USA). The nociceptive scores
were analyzed using a two-way Anova with Bonferroni’s
post hoc test. The p value (the value of probability) as
well as inferential statistics - F test [38,39], which
include information about the obtained magnitude or
value of the test statistic and degrees of freedom, are
represented.
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